Recently, Nanjing King-Friend Biochemical Pharmaceutical Co.,LTD. (hereinafter referred to as "King-Friend") has obtained the drug registration certificate issued by the National Medical Products Administration for its Fulvestrant Injection, officially approving its domestic marketing and sale.

Fulvestrant Injection can be used for postmenopausal (including natural menopause and artificial menopause) estrogen receptor-positive locally advanced or metastatic breast cancer that recurs after or during anti-estrogen adjuvant therapy, or progresses during anti-estrogen therapy.

With the approval of fulvestrant injection in the Chinese market, innovative therapies that meet top international standards will accelerate their benefits for domestic patients, helping to enhance their treatment experience and health well-being.